↓ Skip to main content

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed

Overview of attention for article published in BMC Cancer, July 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
19 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed
Published in
BMC Cancer, July 2016
DOI 10.1186/s12885-016-2457-0
Pubmed ID
Authors

Sojung Park, Hyun Jung Kim, Chang–Min Choi, Dae Ho Lee, Sang–We Kim, Jung–Shin Lee, Woo Sung Kim, Se Hoon Choi, Jin Kyung Rho, Jae Cheol Lee

Abstract

Pemetrexed is widely used for the treatment of advanced non-squamous non-small-cell lung cancer (NSCLC). However, factors that can predict the benefits of pemetrexed therapy have not yet been defined. We compared the clinical and molecule pathological characteristics of good and poor responders among a cohort of 1,848 non-squamous NSCLC patients who had received at least two cycles of pemetrexed therapy between November 2006 and February 2015. Among these cases, 92 good responders who were the top 5 % in terms of progression-free survival (PFS) and 222 poor responders who had progressive disease after only 2 cycles of therapy were selected for the analysis. The median PFS of the good responders was 29.9 months (range; 20.9-90.0) and the median number of cycle was 37 (range; 18-129). Although 53.5 % of patients showed stable disease (SD), this response was sustained (median PFS in SD, 29.6 months). A never-smoking status was related to better survival outcome, whereas EGFR mutation, two or more metastatic sites, and intra-abdominal metastasis were each associated with a poor PFS. ALK translocation showed a tendency for a positive impact on response to pemetrexed, whereas metastatic lesion to liver, adrenal gland or bone showed a tendency for a negative impact despite not reaching our threshold for statistical significance. Predictive factors, such as smoking status, the status of genetic alteration and tumor burden, should be considered when administering pemetrexed therapy for non-squamous NSCLC.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 5%
Unknown 18 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 26%
Student > Bachelor 3 16%
Other 2 11%
Student > Ph. D. Student 2 11%
Professor 1 5%
Other 4 21%
Unknown 2 11%
Readers by discipline Count As %
Medicine and Dentistry 7 37%
Agricultural and Biological Sciences 2 11%
Biochemistry, Genetics and Molecular Biology 2 11%
Psychology 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Other 2 11%
Unknown 4 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2016.
All research outputs
#6,054,345
of 8,372,629 outputs
Outputs from BMC Cancer
#1,952
of 3,517 outputs
Outputs of similar age
#166,563
of 261,489 outputs
Outputs of similar age from BMC Cancer
#105
of 230 outputs
Altmetric has tracked 8,372,629 research outputs across all sources so far. This one is in the 24th percentile – i.e., 24% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,517 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,489 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 230 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.